No Survival Difference With or Without Pacemaker After TAVR No Survival Difference With or Without Pacemaker After TAVR
Long-term survival between patients who did and did not undergo permanent pacemaker implantation after transcatheter aortic valve replacement showed no differences in the SWEDEHEART cohort study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Abbott's Epic ™ Plus Tissue Valves for People in Need of Mitral or Aortic Valve Replacement
- New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures (Source: Abbott.com)
Source: Abbott.com - September 22, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives FDA Approval for Minimally Invasive Portico ™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
- Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery (Source: Abbott.com)
Source: Abbott.com - September 20, 2021 Category: Pharmaceuticals Source Type: news

COVID-19 Is Forcing Us to Talk About Rationing Health Care in the U.S. Again. Could We Have Avoided This?
On Sept. 7, the country’s leading COVID-19 doctor issued a dire warning about the growing number of pandemic cases in the country, and the shrinking number of ICU beds available to care for the sickest people. Speaking on CNN, Dr. Anthony Fauci, the chief White House medical advisor, said we are “perilously close in certain areas of the country of getting so close to having full occupancy that you’re going to be in a situation where you’re going to have to make some tough choices.” Those tough choices, he admitted, include discussions about whether scarce resources should go to people who have...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

What are Some of the Complications of Short Bowel Syndrome?
Discussion Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in neonates. Mortality rates are from 0-45% depending on infant weight and gestation with more premature and smaller infants having greater mortality. NEC usually occurs in premature infants but it also occurs in term infants. The etiology is unknown but is probably multifactorial with ischemia and/or reperfusion playing some role. There are ‘outbreaks’ of NEC but no causative organism has been identified. Regardless of the originating cause, inflammation of the intestine and release of inflammatory mediators cause...
Source: PediatricEducation.org - August 30, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AI Hones in on CMR Markers of Mortality in Aortic Stenosis AI Hones in on CMR Markers of Mortality in Aortic Stenosis
Machine learning identified thresholds for cardiovascular magnetic resonance risk markers for mortality after surgical or transcatheter aortic valve replacement.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 11, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Echocardiography can determine patient risk in COVID-19 cases
Transthoracic echocardiography is helpful in determining mortality risk fo...Read more on AuntMinnie.comRelated Reading: CT shines when it comes to COVID-19 risk stratification Prenatal detection of heart defects low in Hispanic women, poor areas Echo helps identify flossing-induced heart disease Women have more chest pain despite less stenosis on CCTA ACC: Echocardiography identifies patients for valve repair (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 21, 2021 Category: Radiology Source Type: news

Psychiatry Is Still Stuck in Freud ’s Era. Big Data Can Revolutionize How We Care for Patients
I have a problem. I am a psychiatrist in the 21st century and yet I still evaluate patients the way Freud did a century ago: I sit with a patient and, by carefully observing how and what they say, I expect them to tell me what’s wrong. The problem isn’t that I speak with and listen to my patients. Every doctor of every speciality does that. Rather, my problem is that I never measure the data I think are most important to my treatment of psychiatric diseases. Consider how I evaluate a patient for psychosis in the emergency room. When I speak with them, I want to know what their life is like—what’s th...
Source: TIME: Health - July 9, 2021 Category: Consumer Health News Authors: Daniel Barron Tags: Uncategorized Source Type: news

Mayo Clinic first to use next generation 4D ICE imaging to help patients with structural heart disease
Mayo Clinic recently became the first to use a next-generation 4D intracardiac echo (ICE) device in patients to guide heart procedures such as left atrial appendage closure, mitral valve repair and treatment of tricuspid valve regurgitation. The technology can also help physicians perform procedures without putting patients under general anesthesia. An echocardiogram is a noninvasive test that uses sound waves to produce detailed images of the heart's size, structure and function, as well as detailed images of… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 1, 2021 Category: Databases & Libraries Source Type: news

RSNA announces 2021 meeting highlights
The RSNA has announced program highlights ahead of its 2021 annual meeting t...Read more on AuntMinnie.comRelated Reading: RSNA announces MIDRC funding program RSNA R&E grant study identifies new biomarker for NSCLC RSNA plans for in-person meeting in 2021 Top healthcare trends on display at RSNA 2020 FDG-PET/CT within a year of heart valve surgery looks safe (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2021 Category: Radiology Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure
There does not appear to be a benefit to postoperative heparin bridging in patients with atrial fibrillation or a mechanical heart valve who temporarily stop taking warfarin before a planned procedure, according to results of the PERIOP2 study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 18, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ATLANTIS Hints at How to Choose Post-TAVR Antithrombotics ATLANTIS Hints at How to Choose Post-TAVR Antithrombotics
A persisting conundrum: should patients receive oral anticoagulation or antiplatelet therapy after transcatheter aortic valve replacement? A randomized trial offers new clues.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Study reveals need for equitable access of minimally invasive heart procedure
(Society for Cardiovascular Angiography and Interventions) An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United States hospitals is being presented as late-breaking clinical science at the Society for Cardiovascular Angiography& Interventions (SCAI) 2021 Scientific Sessions. The findings indicate that TAVR hospital programs are predominately located in metropolitan areas serving patients with higher socioeconomic status, potentially contributing to the disparities in cardiac care. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 29, 2021 Category: International Medicine & Public Health Source Type: news

Can Minimally Invasive SAVR Challenge TAVR? Can Minimally Invasive SAVR Challenge TAVR?
Cardiologist Wayne Batchelor talks with cardiothoracic surgeon Tom Nguyen about his experience with minimally invasive aortic valve replacement surgery.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Abbott Receives CE Mark Approval for Next-Generation TriClip(TM) Device, Offering New Innovations for Tricuspid Heart Valve Repair
New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy TriCl... Devices, Interventional, Cardiology, Regulatory Abbott, TriClip, Transcatheter, Tricuspid Valve Repair, Tricuspid Valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 8, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives CE Mark Approval for Next-Generation TriClip ™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve (Source: Abbott.com)
Source: Abbott.com - April 8, 2021 Category: Pharmaceuticals Source Type: news

Medtronic Receives FDA Approval for "Breakthrough" Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease
Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony ™ Transcatheter Pulmonary Valve (TPV), the 1st minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle, one of the four chambers of the heart, which makes it difficult for blood to travel from the heart to the lungs. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 26, 2021 Category: Cardiology Source Type: news

Lab-Made Heart Valves Can Grow Along With Youngest Heart Patients
MONDAY, March 22, 2021 -- Lab-created heart valves that grow with the recipient could spare kids born with heart defects from the repeated valve-replacement surgeries they now endure. University of Minnesota researchers found that lab-created valves... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2021 Category: General Medicine Source Type: news

Tri-tube heart valve replacement adapts to the growing heart in lambs
(American Association for the Advancement of Science) Combining tissue engineering and regenerative medicine, scientists have fabricated a series of heart valve replacements with the ability to incorporate host cells, enabling them to regenerate and grow over time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Lab-created heart valves can grow with the recipient
(University of Minnesota) Groundbreaking discovery could potentially reduce multiple pediatric heart valve replacement surgeries. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 17, 2021 Category: Biology Source Type: news

Apollo Hospitals highlights importance of MitraClip therapy for high surgical risk patients
The minimally invasive method used in MitraClip therapy allows repair of a leaking mitral valve without open-heart surgery, Apollo Hospitals said. (Source: The Economic Times)
Source: The Economic Times - March 16, 2021 Category: Consumer Health News Source Type: news

DOACs Offered After Heart Valve Surgery Despite Absence of Data DOACs Offered After Heart Valve Surgery Despite Absence of Data
Use of direct oral anticoagulants (DOACs), contraindicated for patients with mechanical or bioprosthetic valves, has increased steadily for surgical bioprosthetic valve replacement.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 10, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

CHI St. Vincent Infirmary Named a Center of Excellence
CommonSpirit Health has designated CHI St. Vincent Infirmary in Little Rock a Center of Excellence for both transcatheter aortic valve replacement (TAVR) and transcatheter edge-to-edge repair (TEER) heart procedures. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - March 8, 2021 Category: American Health Source Type: news

Delirium Common, Costly After Mitral, Tricuspid Valve Repair Delirium Common, Costly After Mitral, Tricuspid Valve Repair
The incidence was similar to that seen after transcatheter aortic valve replacement and, likewise, associated with worse outcomes in a cohort of elderly patients.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 3, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

How Common are Aortic Aneurysms?
Discussion Aortic root dilatation or thoracic aortic aneurysm occurs in 6:100,000 individuals> 50 years of age. It is due to aging, hypertension, hypercholesterolemia, and smoking. Tertiary syphilis was a cause in the preantibiotic era. Pediatric aneurysms are very uncommon but the exact prevalence is different due to the various causes. Aneurysms are due to genetic disorders, congenital anomalies or post-surgical repair. In pediatric patients with sudden cardiac deaths, 5.4% are due to ruptured thoracic aortic aneurysms. Learning Point Some causes of pediatric aneurysms include: Familial thoracic aneurysm and dissecti...
Source: PediatricEducation.org - February 22, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Upsides, Downsides for TAVR, Minimally Invasive AVR Upsides, Downsides for TAVR, Minimally Invasive AVR
Minimally invasive aortic valve replacement seems to be associated with a lower risk of midterm mortality, while TAVR was associated with shorter hospitalizations and a lower risk of AKI, in a meta-analysis.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 19, 2021 Category: Intensive Care Tags: Cardiology News Source Type: news

SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials
Many patients who are excluded from clinical trials comparing transcatheter aortic-valve replacement with surgical aortic-valve replacement appear to do well with the latter approach, according to researchers in Canada.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Houston Methodist first in Houston to perform TriClip procedure
(Houston Methodist) Cardiologists at Houston Methodist recently performed the first catheter-based repair in Houston of a leaky tricuspid valve using the novel TriClip system. Using cardiac ultrasound guidance, doctors were able to implant two TriClip devices in a 75-year-old patient as part of the pivotal TRILUMINATE trial, which seeks to evaluate the safety and efficacy of the device. The tricuspid valve has traditionally required conventional open-heart surgery to repair or replace it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

Structural Valve Deterioration at 5 Years of TAVR Versus SAVR Structural Valve Deterioration at 5 Years of TAVR Versus SAVR
Does bioprosthetic valve failure occur more frequently with transcatheter aortic valve replacement compared with surgical replacement?Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

TAVR Volumes in the U.S. Have Risen Each Year Since 2011
THURSDAY, Nov. 19, 2020 -- The volume of transcatheter aortic valve replacement (TAVR) procedures in the United States increased from 2011 to 2019, exceeding surgical aortic valve replacements in 2019, and 30-day mortality and stroke rates have... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Opioid epidemic leads to more, younger people having heart valve operations
ROCHESTER, Minn. ? The opioid epidemic in the U.S. is becoming a bigger problem medically, socially and financially, and the COVID-19 pandemic has made it worse, according to the Food and Drug Administration. Heart surgeons have seen a disturbing trend over the past decade: more and younger patients with infective endocarditis requiring heart surgery. Infective [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - October 28, 2020 Category: Hospital Management Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Survival Rate of Heart Valve Replacement Surgery
Title: Survival Rate of Heart Valve Replacement SurgeryCategory: Diseases and ConditionsCreated: 10/23/2020 12:00:00 AMLast Editorial Review: 10/23/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - October 23, 2020 Category: Cardiology Source Type: news

Results from the REFLECT II Trial reported at TCT Connect
(Cardiovascular Research Foundation) The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news

New bioprosthetic valve for TAVR fails to demonstrate non-inferiority
(Cardiovascular Research Foundation) In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news

Medtronic Launches Head-to-Head TAVR Study Comparing the Evolut(TM) TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN, Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT), a global leader in structural heart therapi... Devices, Interventional, Cardiology Medtronic, transcatheter aortic valve replacement (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 14, 2020 Category: Pharmaceuticals Source Type: news

Outcomes Worse for Deferred Aortic Valve Replacement
FRIDAY, Oct. 2, 2020 -- For patients with symptomatic severe aortic stenosis, deferred aortic valve replacement (AVR) is associated with an increased risk for hospitalization for valve-related symptoms or worsening heart failure, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2020 Category: Pharmaceuticals Source Type: news

Patients deferred for transcatheter aortic valve replacement because of COVID-19
(JAMA Network) This single-center study of 77 patients describes the outcomes of patients with symptomatic severe aortic stenosis during the COVID-19 pandemic. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news

Aortic valve replacement during COVID-19 pandemic
(JAMA Network) The outcomes associated with deferred compared with expedited aortic valve replacement in patients with severe aortic stenosis during the COVID-19 pandemic are evaluated in this observational study. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news

Valvular AFib Heightens Risk in TAVR Valvular AFib Heightens Risk in TAVR
Atrial fibrillation confers an increased risk for poor outcomes after transcatheter aortic valve replacement (TAVR), but it is not clear how the etiology of AFib influences post-TAVR outcomes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

‘I Had Heart Surgery in the Middle of a Coronavirus Hot Spot’
Anxiety and uncertainty about the pandemic is leading some patients to delay surgery. But how safe is that when you have an aneurysm in your heart? (Source: NYT Health)
Source: NYT Health - September 22, 2020 Category: Consumer Health News Authors: Johnny Diaz Tags: Coronavirus (2019-nCoV) Surgery and Surgeons Hospitals Aneurysms Miami Beach (Fla) Florida New York City Covid-19 precautions valve sparing aortic root repair. Heart Quarantines Mount Sinai Medical Center aortic aneurysm Source Type: news

Abbott Receives CE Mark for Next-Generation MitraClip ™ Heart Valve Repair Device to Treat Mitral Regurgitation
- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology (Source: Abbott.com)
Source: Abbott.com - September 21, 2020 Category: Pharmaceuticals Source Type: news

Valve-in-valve TAVI in Failed Aortic Bioprosthetic Valves Valve-in-valve TAVI in Failed Aortic Bioprosthetic Valves
Transcatheter aortic valve-in-valve implantation seems a viable alternative to redo surgery in patients with failed bioprosthetic valves, but major concerns about long-term outcomes persist.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Transcatheter Tricuspid Valve Repair for Right Heart Failure Transcatheter Tricuspid Valve Repair for Right Heart Failure
Tricuspid valve regurgitation has long been understudied and undertreated, but new studies are advancing our understanding of transcatheter tricuspid valve edge-to-edge repair for right-sided HF.JACC: Heart Failure (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 21, 2020 Category: Surgery Tags: Cardiology Journal Article Source Type: news